Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target

Maria Trovato¹, Alfredo Campenni², Salvatore Giovinazzo¹, Massimiliano Siracusa² and Rosaria Maddalena Ruggeri¹

¹Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, Italy. ²Department of Biomedical Sciences and Morphological and Functional Images, Unit of Nuclear Medicine, University of Messina, Messina, Italy.

ABSTRACT: The hepatocyte growth factor (HGF)/c-met axis plays a crucial role in cancer development by promoting cellular proliferation, motility, and morphogenesis, as well as angiogenesis. Different cellular distributions of both the ligand and the receptor in benign vs malignant lesions indicate this biological system as a candidate for a diagnostic biomarker of malignancy occurring in endocrine glands, such as the thyroid and pituitary. Furthermore, the HGF/c-met expression may help to identify a subset of patients eligible for potential targeted therapies with HGF/c-met inhibitors or antagonists in thyroid tumour, as well as in other malignancies. This may be relevant for iodine-refractory cancers, the treatment of which is still a major challenge. With this in mind, HGF/c-met expression in thyroid cancer tissue may be useful for prognostic and therapeutic stratification of patients.

KEYWORDS: HGF/c-met axis, diagnostic biomarker, therapeutic target, thyroid cancer

RECEIVED: December 4, 2016. ACCEPTED: March 3, 2017.

PEER REVIEW: Six peer reviewers contributed to the peer review report. Reviewers’ reports totalled 1662 words, excluding any confidential comments to the academic editor.

TYPE: Concise Review

FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Introduction

Differentiated thyroid carcinoma (DTC) represents the most frequent endocrine cancer, and its incidence has been increasing in the past few decades. According to the epidemiological data of Surveillance, Epidemiology, and End Results (SEER), the annual incidence of thyroid cancer has increased from 5.9 to 17.3 cases per 100,000 individuals from 2005 through 2009.¹ Incidence in 2012 in the United States rose to 15 cases per 100,000 individuals per year, and it has been estimated that by 2019 it will increase to 23.8 cases per 100,000 individuals per year.² However, the mortality rate of thyroid cancer has remained stable over time, confirming the overall favourable long-term prognosis of this cancer.¹ Also, the epidemiologic distribution of thyroid cancer histotypes has changed over the past 20 years.³,⁴ The percentage of aggressive follicular and undifferentiated carcinomas has drastically reduced in favour of the papillary counterpart, often diagnosed at less than 1 cm in maximum diameter (the so-called microcarcinoma), whereas noninvasive follicular neoplasms have recently been declassified from thyroid cancer.⁵,⁶ Also, the clinical presentation of DTC has drastically changed, evolving towards an increasing number of cancers being diagnosed at early stage or serendipitously, which is associated with less aggressive behaviour and better prognosis.⁶,⁷ Less than 20% of patients present with advanced or aggressive cancers, with recurrent and/or metastatic disease that significantly impacts survival.⁸,⁹ Finally, about 5% of patients with clinical DTC develop iodine-refractory cancer, which is associated with a survival rate lower than 10% at 10 years.¹⁰ Given these observations, progress in the management of DTC may be achieved by translation of molecular findings in thyroid cancer to the clinical setting. First, recognizing the molecular characteristics that are associated with a more aggressive behaviour of the tumour and a poorer outcome may help to identify patients at higher risk of recurrence and/or distant metastases. Second, identification of proliferative, antiapoptotic, or angiogenic pathways, which are activated in metastatic and/or refractory cancers, may provide the basis for molecular-targeted therapies. In this light, we reviewed data on hepatocyte growth factor (HGF)/c-met axis expression/activation in thyroid disease and on its possible usefulness as a prognostic and therapeutic biomarker in thyroid cancer.

Data Source

The terms ‘HGF’, ‘c-met’, and ‘Thyroid disease, Thyroid nodule(s), Thyroid carcinoma’ were used both separately and in reciprocal conjunction to search MEDLINE for articles published from January 1996 up to December 2016.

Current State of Knowledge: Identified Biology of HGF/c-met

Since HGF was isolated in 1983 as a serum factor appearing after partial hepatectomy, several effects on cellular growth, motility, and morphogenesis have been reported.¹¹ Mainly, HGF protein consists of a heterodimeric structure including 2 chains, 69-kDa α (heavy chain) and 34-kDa β (light chain), by

Keywo RDS: Hepatocyte growth factor (HGF)/c-met axis, diagnostic biomarker, therapeutic target, thyroid cancer
This is a proto-oncogene product belonging to the tyrosine-kinase receptor family that, upon binding of the specific ligand and activation of the tyrosine-kinase domain, provides multiple binding sites for SH2 molecules through autophosphorylation of Tyr 1349 and Tyr 1356. These molecules act as intracellular transducers by recruiting and activating several effectors, including phosphatidylinositol 3-kinase (PI3-kinase), rat sarcoma (Ras), adaptors GRB2 and SHC, the docking protein Gab1, and STAT3. Through HGF binding to c-met, specific intracellular effectors are activated to promote different cellular responses, such as proliferation, cell scattering, and morphogenesis. For instance, the scattering effect of HGF/c-met is mediated by PI3-kinase effectors, whereas the proliferative action is mediated by GRB2 and Ras, and the morphogenetic action is mediated by STAT3, a member of the signal transducers and activators of transcription family (SH2, Src homology 2; SIE, sis-inducible element; STAT3, signal transducer and activator of transcription 3).
Similar to other tumours,\textsuperscript{27-29} the cornerstone evidence supporting HGF and c-met utility in the diagnosis of thyroid malignant lesions is built on evidence of specific cellular localizations for each member of the HGF/c-met

| STUDY          | THYROID LESIONS          | HGF EXPRESSION | C-MET EXPRESSION |
|----------------|---------------------------|----------------|------------------|
|                |                           | NO. (%) OF POSITIVE CASES | NO. (%) OF POSITIVE CASES |
| Koo et al\textsuperscript{34} | Micro-PTC (n = 113)       | 107 (95)        | 103 (91)         |
| Ruggeri et al\textsuperscript{25} | Normal thyroid (n = 6)     | 0              | 0                |
|                | Colloid/hyperplastic nodules (n = 48) | 12 (25)       | 12 (25)          |
|                | FA (n = 20)               | 4 (20)          | 4 (20)           |
|                | OA (n = 15)               | 5 (33)          | 5 (33)           |
|                | PTC (n = 20)              | 20 (100)        | 20 (100)         |
|                | FTC (n = 16)              | 0              | 0                |
|                | ATC (n = 6)               | 0              | 0                |
| Ruggeri et al\textsuperscript{25} | Colloid nodules + HT (n = 25) | 25 (100)     | 25 (100)         |
|                | Colloid nodules (n = 25)  | 7 (28)          | 7 (28)           |
| Scarpino et al\textsuperscript{36} | PTC (n = 64)              | Not tested      | 64 (100)         |
| Trovato et al\textsuperscript{33} | FA (n = 10)               | 2 (20)          | 2 (20)           |
|                | PTC (n = 12)              | 12 (100)        | 12 (100)         |
|                | FTC (n = 10)              | 0              | 0                |
|                | ATC (n = 6)               | 0              | 0                |
| Ramirez et al\textsuperscript{31} | PTC (n = 42)              | 40 (95)         | 37 (88)          |
|                | FC (n = 7)                | 7 (71)          | 5 (71)           |
|                | MTC (n = 2)               | 2              | 1                |
|                | Benign thyroid lesions (n = 14) | Low expression (no further specified) | Low expression (no further specified) |
| Oyama et al\textsuperscript{30} | Normal thyroid (n = 5)     | Not tested      | 0                |
|                | HT/GD (n = 2)             | 0              | 0                |
|                | Adenomatous goitre (n = 8) | 0              | 0                |
|                | FA (n = 8)                | 1 (11)          | 1 (11)           |
|                | PTC (20)                  | 20 (100)        | 20 (100)         |
|                | Undifferentiated carcinomas (2) | 0          | 0                |
| Trovato et al\textsuperscript{24} | Normal thyroid (n = 10)    | 0              | 0                |
|                | Colloid nodules (n = 10)  | 3 (30)          | 3 (30)           |
|                | FA (n = 10)               | 2 (20)          | 2 (20)           |
|                | OA (n = 7)                | 2 (28)          | 2 (28)           |
|                | PTC (14)                  | 12 (86)         | 13 (93)          |
|                | FTC (n = 5)               | 0              | 0                |
|                | Poorly differentiated/ATC (n = 4) | 0          | 0                |

Abbreviations: ATC, anaplastic thyroid cancer; FA, follicular adenoma; FC, follicular carcinoma; FTC, follicular thyroid cancer; GD, Graves’ disease; HGF, hepatocyte growth factor; HT, Hashimoto’s thyroiditis; OA, oncocytic adenoma; PTC, papillary thyroid carcinoma.
axis. When thyroid benign lesions shift towards malignancy, the HGF/c-met cellular disposition is dysregulated to the extent that abnormal epithelial cells can simultaneously express the ligand and the receptor. Among thyroid cancers, papillary thyroid carcinoma (PTC) is associated with marked overexpression (up to 100-fold) of HGF/c-met, which, instead, is rarely expressed in other histotypes, such as follicular, anaplastic, and/or medullary thyroid cancer (Figure 2). Overexpression of HGF/c-met has been found in 75% to 100% of PTC, regardless of the histological variants (Table 1). Our group has also correlated the expression of HGF/c-met with that of STAT3, which is known to mediate morphogenetic effects, suggesting that this autocrine pathway may be relevant for the establishment of the papillary phenotype.

In addition, HGF/c-met expression by tumour cells has been related to metastatic spread and a worse prognosis. Besides its antiapoptotic and proliferative effects, HGF/c-met promotes cellular motility and invasion (hence the name scatter factor). Thus, its expression may distinguish more advanced and aggressive cancers at higher risk of metastatic dissemination.

From these phenomena, 2 consequences of HGF/c-met mechanisms of action have been noted: first, in noncancerous growth, HGF appears as a mesenchymal cytokine adopting paracrine loops to bind c-met localized in adjacent epithelial cells. Conversely, in malignant nodules, gain of HGF expression on epithelial cells indicates an improvement in the ability of HGF to use autocrine mechanisms. Some data reporting LOH occurring in HGF and the c-met gene region have recorded HGF epithelial expressions in PTC which were never associated with loss of genetic material for microsatellite markers pertaining to HGF or c-met. Furthermore, LOH in HGF and c-met gene regions has been observed in follicular and anaplastic thyroid carcinomas only, both failing to express the HGF/c-met axis. These features together strongly imply an HGF involvement in the aberrant epithelial growth of PTC.

Future Perspective: Ongoing Therapeutic Strategies

As a result of the cellular responses induced through HGF/c-met axis in cancer tissues, both HGF and c-met represent an attractive target for personalized antitumour strategies. Recently, there has been much interest in the prognostic and therapeutic implications of the expression of members of the HGF/c-met axis by several epithelial and nonepithelial malignancies, arising from both endocrine and nonendocrine tissues. The identification of biomarkers of response will lead to more effective targeting of this pathway for cancer therapy. Therefore, if the HGF/c-met axis is to be used as a target for treatment, it will be important to identify predictive biomarkers to select those patients likely to benefit. Potential predictive biomarkers for anti-HGF/c-met–targeted therapies should include the immunohistochemical expression of molecules such as c-met, phospho-c-met, HGF, and downstream signalling proteins (RAS-MAPK, PI3K-AKT, and STAT3, to name a few). These putative predictive biomarkers should be evaluated for therapeutic stratification of patients.

Immunohistochemical profiles of the HGF/c-met pathways depict several cancers, including PTC and colon carcinomas, as well as pituitary adenomas, which may benefit from these novel therapeutic agents.

Several drugs targeting HGF/c-met have been developed and are now being tested in clinical trials with encouraging results. These include anti-met and anti-HGF monoclonal antibodies and antagonists of biological HGF, to be used alone or in combination with tyrosine-kinase inhibitors. Among c-met inhibitors, few agents have proved to be capable of cutting off the HGF signal. Mainly, the non–adenosine triphosphate competitive c-met inhibitor, tivantinib (ARQ 197), when combined with erlotinib, has shown an appreciable response rate in phase 3 study of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Rilotumumab (AMG102) has been reported as the humanized anti-HGF monoclonal antibody capable of blocking HGF/c-met signals by preventing HGF binding to c-met. In
### Table 2. Clinical trials adopting HGF antagonist or anti–c-met drug agents in cancer therapy.

| START DATE | STUDY | CANCER TYPES | INFORMATION PROVIDED BY | CLINICAL TRIALS GOV IDENTIFIER | DRUG AGENTS | DRUGS COMBINED | PHASE OF STUDY | COMPLETION DATE | CONCLUSIONS |
|------------|-------|--------------|--------------------------|-------------------------------|-------------|----------------|----------------|-----------------|-------------|
| 2009       | A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 | Advanced solid tumours | Millennium Pharmaceuticals, Inc. | NCT00831896 | TAK-701 | — | 1 | 2011 | Completed |
| 2010       | Multicenter Phase 2 Trial of ARQ 197 | Non-CNS germ cell tumours (seminomas and nonseminomas) | Daiichi Sankyo Inc. | NCT01055067 | Tivantinib (ARQ 197) | — | 2 | 2012 | Completed |
| 2011       | Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor | Stomach cancer, malignant mesenchymal tumour soft tissue sarcoma | National Cancer Institute (NCI) | NCT01468922 | Tivantinib (ARQ 197) | Pazopanib | 1 | 2016 | Completed |
| 2011       | Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) | Metastatic non–small cell lung cancer | ArQule | NCT01395758 | Tivantinib (ARQ 197) | Erlotinib | 2 | 2016 | Completed |
| 2011       | Study Evaluating Efficacy and Safety of Onartuzumab (MetMab) | Nonsquamous non–small cell lung cancer | Genentech, Inc. | NCT01456325 | Onartuzumab (MetMab) | Erlotinib | 3 | 2016 | Completed |
| 2012       | RILOMET-I | Gastric, lower oesophageal, or gastrooesophageal junction adenocarcinoma | Amgen | NCT01697072 | Rilotumumab (AMG3102) | — | 3 | 2015 | Stopped |
| 2012       | Double-Blind Study of Tivantinib (ARQ 197) | Hepatocellular carcinoma | Daiichi Sankyo Inc. | NCT01755767 | Tivantinib (ARQ 197) | — | 3 | 2017 | Ongoing |
| 2012       | Study Evaluating the Efficacy and Safety of MetMab | Nonsquamous non–small cell lung cancer | Genentech, Inc. | NCT01496742 | Onartuzumab (MetMab) | Cisplatin and carboplatin | 2 | 2015 | Completed |
| 2012       | Study Evaluating the Efficacy and Safety of Onartuzumab (MetMab) | Glioblastoma | Hoffmann-La Roche | NCT01632228 | Onartuzumab (MetMab) | Bevacizumab | 2 | 2016 | Completed |

(Continued)
| START DATE | STUDY | CANCER TYPES | INFORMATION PROVIDED BY | CLINICALTRIALS GOV IDENTIFIER | DRUG AGENTS HGF ANTAGONISTS | ANTI-MET | DRUGS COMBINED | PHASE OF STUDY | COMPLETION DATE | CONCLUSIONS |
|------------|-------|--------------|-------------------------|-------------------------------|----------------------------|---------|----------------|-----------------|-----------------|-------------|
| 2012       | Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) | Metastatic human epidermal growth receptor (HER) 2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction | Hoffmann-La Roche | NCT01662869 | Onartuzumab (MetMAb) | 5-fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) | 3 | 2015 | Completed |
| 2013       | Study Evaluating The Safety, Tolerability, and Pharmacokinetics of Onartuzumab | Advanced hepatocellular carcinoma | Hoffmann-La Roche | NCT01897038 | Onartuzumab (MetMAb) | Sorafenib | 1 | 2015 | Completed |
| 2013       | Study Evaluating the Efficacy and Safety of Onartuzumab | Non–small cell lung cancer | Hoffmann-La Roche | NCT01887886 | Onartuzumab (MetMAb) | Erlotinib | 3 | 2015 | Completed |
| 2013       | Study Evaluating LY2875358 | Non–small cell lung cancer | Eli Lilly and Company | NCT01900652 | LY2875358 | Erlotinib | 2 | 2015 | Completed |
| 2014       | Study of the Pharmacokinetics and Safety of Onartuzumab in Chinese Patients | Metastatic solid tumours | Hoffmann-La Roche | NCT02031731 | Onartuzumab (MetMAb) | — | 1 | 2014 | Completed |
| 2014       | RILOMET-2 | Gastric or gastroesophageal junction adenocarcinoma | Amgen | NCT02137343 | Rilotumumab (AMG102) | Cisplatin and capecitabine | 3 | 2015 | Stopped |
| 2014       | Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib | Untreated metastatic, EGFR-mutated non–small cell lung cancer | AVEO Pharmaceuticals, Inc. | NCT02318368 | Ficlatuzumab (AV-299) | Erlotinib | 2 | 2017 | Ongoing |

Abbreviations: CNS, central nervous system; HGF, hepatocyte growth factor; vEGFR, vascular endothelial growth factor receptor. Data are taken from ClinicalTrials.gov, a service of the US National Institutes of Health (https://clinicaltrials.gov/ct2/show/NCT01697072).
vitro, there was evidence demonstrating the inhibition of the HGF signal through rilotumumab-induced apoptosis in cell lines of gastric carcinomas expressing c-met.52 On these promising data, 3 pivotal global phase 3 trials, namely, RILOMET-1, RILOMET-2, and MetGaстрic, were designed on the response of advanced/metastatic gastroesophageal cancer to rilotumumab and to onartuzumab, a humanized monovalent antibody to c-met (c-MetMAb) that neutralizes c-met by inhibiting HGF binding and receptor dimerization.51,52 However, data from RILOMET-1 showed no valid therapeutic efficacy of rilotumumab in terms of overall survival and progression-free survival (PFS), and no subgroups of patients seemed to benefit with rilotumumab, including those with higher percentages of cells expressing c-met.42,43 Both studies, RILOMET-1 and RILOMET-2, were stopped. Also, preliminary results of the MetGaстрic trial showed that the addition of onartuzumab did not improve PFS in the unselected population or in the MET-positive subgroup.42,43 Further study is necessary to determine the combination of targeted therapy that will translate into improved survival.

Finally, an emerging model of cancer plasticity resulting in a phenotype switch from an epithelial to a mesenchymal cellular state may further support the development of new drug targets. Either HGF is released from the surrounding stromal cells, resulting in a constitutive paracrine c-met activation, or coexpression of HGF and c-met leads to autocrine activation, targeting the HGF/c-met pathway may disrupt the interactions between tumour cells and their microenvironment, significantly increasing cancer treatment efficacy.

**Conclusions**

In this review, we have evaluated the present knowledge on HGF/c-met axis expression in thyroid disease with a special point of reference to the impelling demands to look for markers of thyroid cancer that would also serve as therapeutic targets.

Similar to other cancers, HGF/c-met signal expression and cellular distribution in thyroid tumours may help to identify patients eligible for potential targeted therapies with HGF/c-met inhibitors or antagonists. This may be relevant for iodine-refractory cancers, whose treatment is still a challenge.50,51 Moreover, HGF/c-met expression may be used for diagnostic and prognostic applications in the context of other well-accepted clinic-pathological prognostic parameters for DTC (age, gender, pTNM stage, histological subtype, and malignant nodule topography) because very few new markers have revealed prognostic value per se.52–56

**Author Contributions**

MT wrote the first draft of the manuscript. RMR contributed to the writing of the manuscript. MT, AC, SG, MS and RMR jointly developed the structure and arguments for the paper. SG revised English language. MS and AC made critical revisions and approved final version. All authors reviewed and approved the final manuscript.

**Disclosures and Ethics**

The authors have provided to the publisher with signed confirmation of compliance with legal and ethical obligations including, but not limited to, the following: authorship and contributorship, conflicts of interest, privacy, and confidentiality. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. The authors have nothing to disclose.

**REFERENCES**

1. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/ csr/1975_2010/. Published April 2013.
2. Aschebrook-Kilfoy B, Schechter RB, Shih YC, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013;22:1252–1259.
3. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–991.
4. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype – papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7.
5. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Ovaral. 2016;2:1023–1029.
6. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231–236.
7. Ito Y, Urutu T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381–387.
8. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463.
9. Durante C, Montesano T, Torlontano M, et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98:636–642.
10. Schümbeger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–358.
11. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol. 1995;131:1573–1586.
12. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 1993;121:145–154.
13. Ponsetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77:261–271.
14. Pelicci G, Giudano S, Zhen Z, et al. The motogenic and mitogenic responses to HGF are amplified by the SHC adapt protein. Oncogene. 1995;10:1631–1638.
15. Ponsetto C, Zhen Z, Audero E. Specific uncoupling of GRB2 from the Met receptor. J Biol Chem. 1996;14:1419–14123.
16. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 1996;384:173–186.
17. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by hepatocyte growth factor HGF depends on the STAT pathway. J Cell Biol. 1995;131:1573–1586.
18. Maffe A, Comoglio PM. HGF controls branched morphogenesis in tubular glands. Eur J Morphol. 1998;36:74–81.
20. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–848.

21. Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benveniga S, Trovato M. HGF/c-Met system pathway in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization. Histol Histopathol. 2012;27:113–121.

22. Trovato M, Vitarelli E, Grosso M, et al. Immunohistochemical expression of HGF, c-met and transcription-factor STAT3 in colorectal tumors. Eur J Histochim. 2004;48:291–297.

23. Trovato M, Fragetta F, Villari D, et al. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. J Clin Endocrinol Metab. 1999;84:3235–3240.

24. Trovato M, Villari D, Bartolone L, et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid. 1998;8:125–131.

25. Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M. The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor isoforms in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization. J Endocrinol Invest. 2010;34:624.

26. Ruggeri RM, Sciacchitano S, Cardelli P, et al. Serum hepatocyte growth hormone (HGF) is increased in Hashimoto's thyroiditis either or nor associated with nodular goiter as compared with healthy non goitrous individuals. J Endocrinol Invest. 2009;32:465–469.

27. Elliott BE, Hung WL, Boag AH, Tuck AB. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol. 2002;80:91–102.

28. Toshiya Y, Yasuda H, Saitou S, et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 2012;130:2912–2921.

29. Ferrucci A, Moschetta M, Frassanito MA, et al. A HGF/cMET autocrine loop governs epithelial-to-mesenchymal plasticity in papillary thyroid carcinomas and a subset of follicular adenomas. J Endocrinol. 2015;218:487–494.

30. Oyama T, Ichimura E, Sano T. C-Met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Res Pract. 1998;198:763–768.

31. Oyama T, Ichimura E, Sano T. C-Met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Res Pract. 1998;198:763–768.

32. Di Renzo MF, Olivero M, Serini, et al. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest. 1995;18:134–139.

33. Oyama T, Ichimura E, Sano T. C-Met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Res Pract. 1998;198:763–768.

34. Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benveniga S, Trovato M. The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor isoforms in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization. J Endocrinol Invest. 2010;34:624.

35. Koo BS, Kim JM, Seo ST, et al. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 2014;21:2310–2317.

36. Scarpino S, Cancellari d'Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol. 2004;202:352–358.

37. Scarpino S, Stoppacciaro A, Colarossi C, et al. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. J Pathol. 1999;189:570–575.

38. Scarpino S, Durante E, Stoppacciaro A, et al. COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. J Endocrinol Invest. 2014;37:3287–3296.

39. Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor c-MET axis in cancer therapy. J Clin Oncol. 2012;30:3287–3296.

40. Teng L, Lu J. c-MET as a potential therapeutic target in gastric cancer. Int J Mol. 2013;32:1247–1254.

41. Hack SP, Bruey JM, Koeppe H. HGF/MET-directed therapeutics in gastrointestinal cancer: a review of clinical and biomarker development. Oncotarget. 2014;5:2866–2880.

42. Zhang YW. Promise and challenges on the horizon of MET-targeted cancer therapeutics. World J Biol Chem. 2015;6:16–27.

43. Joo MK, Park JJ, Chun HJ. Recent updates of precision therapy for gastric cancer: towards optimal tailored management. World J Gastroenterol. 2016;22:4638–4650.

44. Trovato M, Torre ML, Ragonesi M, et al. HGF/c-Met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. Endocrine. 2013;44:735–743.

45. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013;39:793–801.

46. Scagliotti G, von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2667–2674.

47. Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9:74.

48. Woo J, Cohen SA, Grim JE. Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf). 2015;3:316–329.

49. Alonso-Gondra T, Díez J, Durán M, Grande E. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:22–38.

50. Bulotta S, Celano M, Costante G, Russo D. Emerging strategies for managing differentiated thyroid cancers refractory to radiiodine. Endocrine. 2016;25:214–221.

51. Ruggeri RM, Campennì A, Baldari S, Trimarchi F, Trovato M. What is new on thyroid cancer biomarkers (Review). Biomarkers Insights. 2008;3:237–252.

52. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;5:9.

53. Campennì A, Giovanella L, Alibrandi A, Siracusa M, Ruggeri RM, Baldari S. BRAF (V600E) mutation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. Endocrinology. 2016;137:1489–1499.

54. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013;39:793–801.

55. Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M. Prognostic markers in differentiating benign from malignant follicular-derived thyroid nodules. Clin Pathol. 2003;18:393–399.

56. Campennì A, Giovanella L, Alibrandi A, Siracusa M, Ruggeri RM, Baldari S. BRAF (V600E) mutation in thyroid papillary carcinoma. Clin Endocrinol (Oxf). 2016;84:152–153.